Publications by authors named "Solange Correa Garcia Pires d'Avila"

Article Synopsis
  • - Cisplatin (Cis) is an effective chemotherapy for cervical cancer, promoting DNA damage and apoptosis while influencing the expression of Annexin A1 (ANXA1) and inhibitor of DNA binding 1 (ID1) proteins in cervical cancer tissues and cells.
  • - Observations from cervical tissue samples show a strong presence of ID1 in advanced Cervical Intraepithelial Neoplasia (CIN) stages, and in vitro experiments indicate that Cis treatments, alone or with ANXA1 peptide, boost ANXA1 expression while decreasing ID1 levels.
  • - Treatment with ANXA1 peptide or Cis not only lowers cell growth and survival but also induces late-stage apoptosis and hinders the migration of cervical cancer
View Article and Find Full Text PDF

Background: The incidence of cutaneous melanoma is increasing worldwide. Since it is an aggressive neoplasm, it is difficult to treat in advanced stages; early diagnosis is important to heal the patient. Melanocytic nevi are benign pigmented skin lesions while atypical nevi are associated with the risk of developing melanoma because they have a different histological pattern than common nevi.

View Article and Find Full Text PDF

We report a patient with Chagas' disease that presented Trypanosoma cruzi reactivation after cardiac transplantation and immunodepression, characterized by skin lesions of erythema nodosum. This is an unusual presentation of Chagas' disease.

View Article and Find Full Text PDF

Chromoblastomycosis is a fungal infection caused by dematiaceous fungi inducing skin lesions of difficult treatment and of frequent recurrence. The objective of the present investigation was to characterize cell-mediated tissue reactions in the skin in cases of Chromoblastomycosis using histopathology and immunocytochemistry methods and to correlate them with different clinical forms of Chromoblastomycosis. Biopsies from 19 patients were stained with HE and Giemsa, and serial sections were immunohistochemically stained using CD45RO, CD20, CD4, CD8, CD68, CD1a, CD34, IL4, IL10, TNF-alpha and IFN-gamma antibodies.

View Article and Find Full Text PDF